



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

## **NOMINATION AND REMUNERATION POLICY**

### **1. Preamble**

The Board of Directors of Norris Medicines Limited ("the Company") had constituted a Remuneration Committee consisting of Three (3) Directors, of which the majority was Independent Directors. In order to align with the provisions of the Companies Act, 2013 ("the Act") and the Listing Agreement, the Board renamed the "Remuneration Committee" as "Nomination and Remuneration Committee".

### **2. Objective**

The Nomination and Remuneration Committee and this Policy are in compliance with Section 178 of the Companies Act, 2013 read along with the applicable rules thereto and Regulation 19 of the SEBI (LODR) Regulations, 2015. The Key Objectives of the Committee would be:

- (a) To guide the Board in relation to appointment and removal of Director, Key Managerial Personnel and Senior Management.
- (b) To evaluate the performance of the members of the Board and provide necessary report to the Board for further evaluation of the Board
- (c) To recommend to the Board on Remuneration payable to the Director, Key Managerial Personnel and Senior Management.
- (d) To provide to Key Managerial Personnel and Senior Management reward linked directly to their effort, performance, dedication and achievement relating to the company's operations.
- (e) To retain, motivate and promote talent and to ensure long term sustainability of talented managerial persons and create competitive advantage.
- (f) To devise a policy on Board diversity.
- (g) To develop a succession plan for the Board and to regularly review the plan.

### **3. Definitions**

- (a) "Act" means the Companies Act, 2013 and Rules framed thereunder, as amended from time to time.
- (b) "Board" means Board of Directors of the Company.
- (c) "Key Managerial Personnel" (KMP) means as defined under according to Section 2(51) of the Companies Act, 2013.



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

- (d) "Senior Management" means Senior Management Personnel of the Company who are 'one level below the Key Managerial Personnel".
- (e) "Independent Director" means as defined under section 149(6) of the Companies Act, 2013.

## **4. Role of Committee**

### **I. Matters to be dealt:**

The Committee shall:

- i. Formulate the criteria for determining qualifications, positive attributes and independence of a Director
- ii. Identify persons who are qualified to become Director and persons who may be appointed in Key Managerial and Senior Management positions in accordance with the criteria laid down in this policy.
- iii. Recommend to the Board, appointment and removal of Director, KMP and Senior Management Personnel.

### **II. Policy for appointment and removal**

#### **a. Appointment**

- i. The Committee shall identify and ascertain the integrity, qualification, expertise and experience of the person for appointment as Director, KMP or at Senior Management level and recommend to the Board his / her appointment.
- ii. A person should possess adequate qualification, expertise and experience for the position he / she is considered for appointment. The Committee has discretion to decide whether qualification, expertise and experience possessed by a person are sufficient / satisfactory for the concerned position.
- iii. The Company shall not appoint or continue the employment of any person as Whole-time Director who has attained the age of seventy years. Provided that the term of the person holding this position may be extended beyond the age of seventy years with the approval of shareholders by passing a special resolution based on the explanatory statement annexed to the notice for such motion indicating the justification for extension of appointment beyond seventy years.

#### **b. Term / Tenure**



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

i. **Managing Director / Whole-time Director:**

The company shall appoint or re-appoint any person as its Executive Chairman, Managing Director or Executive Director for a term not exceeding five (5) years at a time. No re-appointment shall be made earlier than one year before the expiry of the term.

ii. **Independent Director:**

- An Independent Director shall hold office for a term upto five consecutive years on the Board of the Company and will be eligible for re-appointment on passing a special resolution by the Company and disclosure of such appointment in the Board's Report.
- No Independent Director shall hold office for more than two consecutive terms, but such Independent Director shall be eligible for appointment after expiry of three years of ceasing to become an Independent Director. Provided that an Independent Director shall not, during the said period of three years be appointed in or be associated with the Company in any other capacity, either directly or indirectly.
- At the time of appointment of Independent Director, it should be ensured that number of Boards on which such Independent Director serves is restricted to seven listed companies as an Independent Director and three listed companies as an Independent Director in case such person is serving as a Whole-time Director of a listed company or such other number as may be prescribed under the Act and Listing Agreement, from time to time.

**c. Evaluation Criteria for Directors**

Performance evaluation is a key mean by which Board can recognize and correct corporate governance issues and add real value to the Company. The Board determines and discusses the reasons for governance failures and how Board evaluations can help prevent them from occurring. All Board members are to participate in the evaluation and are encouraged to further discuss and refine their views during meetings. The following criteria are to be followed for reviewing the directors' performance:-

- i. Accomplishment of organization's mission, objectives and strategic results for which the Executive Director(s) is responsible.



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

- ii. Ensuring that the Board is well informed on issues affecting the continuing relevance of the mission and the performance and reputation of the Company.
- iii. Adequacy of processes which monitor business performance, Board member interaction with management, adequacy of Board knowledge, adequacy of business strategy, Board being informed, evaluation process for executives and Directors.
- iv. Appropriateness of balance and mix of skills, size of Board, contribution of individual Board members, adequacy of performance feedback to Board members, adequacy of procedures dealing with inadequate performance by a Board member.
- v. Board's effectiveness in use of time, whether Board allowed sufficient opportunity to adequately assess management performance, Board's ability to keep abreast of developments in the wider environment which may affect adequacy of meeting, frequency and duration.
- vi. Working relationship between Chairman and Managing Director & Chief Executive Officer, segregation of duties between Board and management in a constructive manner, adequacy of Board discussions and management of divergent views.

The evaluation will take place annually as per the requirement of law and Listing Agreement. The Board may undertake more frequent evaluations, if warranted. The performance evaluation will typically address activities, events and accomplishments that took place during the most recently completed fiscal year.

#### **d. Removal**

Due to reasons for any disqualification mentioned in the Act or under any other applicable Act, rules and regulations thereunder, the Committee may recommend, to the Board with reasons recorded in writing, removal of a Director, KMP or Senior Management Personnel subject to the provisions and compliance of the said Act, rules and regulations

#### **e. Retirement**

The Director, KMP and Senior Management Personnel shall retire as per the applicable provisions of the Act and the prevailing policy of the Company. The Board will have the discretion to retain the Director, KMP, Senior Management Personnel in the same position / remuneration or otherwise even after attaining the retirement age, for the benefit of the Company.



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

### **III. Policy relating to the Remuneration**

#### **a. Remuneration to Chairman, Whole-time / Executive / Managing Director, KMP and Senior Management Personnel:**

- i. Fixed pay: The Whole-time Director / KMP and Senior Management Personnel shall be eligible for a monthly remuneration as may be approved by the Board on the recommendation of the Committee. The breakup of the pay scale and quantum of perquisites including, employer's contribution to P.F., pension scheme, medical expenses, club fees etc. shall be decided and approved by the Board / the person authorized by the Board on the recommendation of the Committee and approved by the shareholders and Central Government, wherever required.
- ii. Minimum Remuneration: If, in any financial year, the Company has no profits or its profits are inadequate, the Company shall pay remuneration to its Whole-time Director in accordance with the provisions of Schedule V of the Act and if it is not able to comply with such provisions, with the previous approval of the Central Government.
- iii. Provisions, for excess remuneration: If any Whole-time Director draws or receives, directly or indirectly by way of remuneration any sums in excess of the limits prescribed under the Act or without the prior sanction of the Central government, where required, he / she shall refund such sums to the Company and until such sum is refunded, hold it in trust for the Company. The Company shall not waive recovery of such sum refundable to it unless permitted by the Central Government.

#### **b. Remuneration to Non – Executive / Independent Director:**

- i. Remuneration: The remuneration / commission shall be fixed as per the terms and conditions mentioned in the Articles of Association of the company and the Act.
- ii. Sitting Fees: The Non-Executive / Independent Director shall receive remuneration by way of fees for attending meetings of Board or Committee thereof, as may be decided by the Board, from time to time. Provided that the amount of such fees shall not exceed Rs. One Lac per meeting of the Board or Committee or such amount as may be prescribed by the Central Government from time to time.
- iii. Commission: commission may be paid within the monetary limit approved by shareholders, subject to the limit not exceeding 1% of the profits of the Company computed as per the applicable provision of the Act. "Differential Commission may be paid to Non – Executive / Independent Directors based



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

on their participation, contribution and active role in the Board and strategic matters of the Company.'

- iv. Stock Options: An Independent Director shall not be entitled to any stock option of the company.

## 5. Membership

- a) The Committee shall consist of minimum three (3) directors, majority of them being Independent.
- b) Minimum two (2) members, one of which must be an Independent Director, shall constitute a quorum for the Committee meeting.
- c) Membership of the Committee shall be disclosed in the Annual Report.
- d) Term of the Committee shall be continued unless terminated by the Board of directors.

## 6. Chairperson

- a) Chairperson of the Committees shall be an Independent Director.
- b) Chairperson of the Company may be appointed as a member of the Committee but shall not be a Chairperson of the committee.
- c) In the absence of the Chairperson, the members of the Committee present at the meeting shall choose one amongst them to act as Chairperson.
- d) Chairman of the Nomination and Remuneration Committee meeting could be present at the Annual General Meeting or may nominate some other member to answer the shareholders' queries.

## 7. Frequency of Meetings

The meeting of the Committee shall be held at such intervals as may be required. However, at least one meeting should be held in a financial year.

## 8. Committee Members' Interests

- a) A member of the Committee is not entitled to be present when his or her own remuneration is discussed at a meeting or when his or her performance is being evaluated.
- b) The Committee may invite such executives, as it considers appropriate, to be present at the meetings of the Committee.

## 9. Secretary

The Company Secretary of the Company shall act as Secretary of the Committee.



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

## 10. Voting

- a) Matters arising for determination at Committee meetings shall be decided by a majority of votes of members present and voting and any such decision shall for all purposes be deemed a decision of the Committee.
- b) In the case of equality of votes, the Chairman of the meeting will have a casting vote.

## 11. Nomination Duties

The duties of the committee in relation to nomination matters include:

- a) Ensuring that there is an appropriate induction process in place for new Directors, KMP's and members of Senior Management and reviewing its effectiveness.
- b) Ensuring that on appointment to the Board, Non-Executive Directors receive a formal letter of appointment in accordance with the Guidelines provided under the Act.
- c) Identifying and recommending Directors who are to be put forward for retirement by rotation.
- d) Determining the appropriate size, diversity and composition of the Board.
- e) Setting a formal and transparent procedure for selecting new Directors for appointment to the Board.
- f) Developing a succession plan for the Board, KMP and Senior Management and regularly reviewing the plan.
- g) Evaluating the performance of the Board members, KMP and Senior Management in the context of the Company's performance from business and compliance perspective.
- h) Making recommendations to the Board concerning any matters relating to the continuation in office of any Director at any time including the suspension or termination of service of an Executive Director as an employee of the Company subject to the provision of the law and their service contract.
- i) Delegating any of its powers to one or more of its members of the Committee.
- j) Recommend necessary changes to the Board.
- k) Consider any other matters, as may be requested by the Board.

## 12. Remuneration Duties

The duties of the Committee in relation to remuneration matters include:



**NORRIS**  
**MEDICINES LIMITED**



**Factory** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Regd. Office** : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
**Telephone** : (02646) 223462, 227530  
**Fax** : (02646) 250126  
**E-mail** : contact@norrispharma.com  
**Website** : www.norrispharma.com  
**CIN** : L24230GJ1990PLC086581

- a) To consider and determine the Remuneration Policy, based on the performance and also bearing in mind that the remuneration is reasonable and sufficient to attract retain and motivate members of the Board, KMP and Senior Management and such other factors as the Committee shall deem appropriate all elements of the remuneration of the members of the Board.
- b) To approve the remuneration of the Senior Management including Key Managerial Personnel of the Company maintaining a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the company.
- c) To delegate any of its powers to one or more of its members of the Committee.
- d) To consider any other matters as may be requested by the Board.
- e) To consider matters relating to Directors & Officers Insurance Policy.

### **13. Minutes of the Committee Meeting**

Proceedings of all meetings must be minuted and signed by the Chairman of the Committee within 30 days from the date of the meeting. Minutes of the committee meetings will be tabled at the subsequent Board and Committee meeting.

### **14. Amendment (s) / Modification (s)**

The Nomination and Remuneration committee will review and may amend / modify this Policy from time to time.